Observational studyDrug design, development and therapy2026
A Prospective Cohort Study on the Impact of SGLT2 Inhibitors on the 12‑Month Recurrence Risk of Atrial Fibrillation After Catheter Ablation.
Observational study in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Catheter ablation (CA) effectively maintains sinus rhythm in atrial fibrillation (AF) patients, but its postoperative recurrence rate remains high (20-40%), necessitating safe and effective adjuvant therapies. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have cardioprotective effects, yet high-quality evidence on their value and impact on AF recurrence post-CA is insufficient. Methods: This single-center observational study prospectively enrolled AF patients undergoing first-time cardiac radiofrequency CA (Jan 2020-Dec 2023). Patients were split into the SGLT2i group (106 cases, 10mg daily dapagliflozin/empagliflozin) and the control group (324 cases). 1:3 propensity score matching (PSM, 13 variables including gender, age, BMI) balanced baselines. Kaplan-Meier analysis compared 12-month AF-free survival; univariate and multivariate Cox models analyzed SGLT2i-AF recurrence association. Results: A total of 430 patients were enrolled, with an overall 12-month AF recurrence rate of 21.63% (93/430). Kaplan-Meier analysis demonstrated higher 12-month AF-free survival in the SGLT2i group (total cohort Log-rank P = 0.019; PSM cohort Log-rank P = 0.016). Multivariate Cox analysis confirmed SGLT2i use was independently associated with a reduced risk of AF recurrence (total cohort: HR = 0.459, 95% CI = 0.228-0.926, P = 0.030; PSM cohort: HR = 0.458, 95% CI = 0.223-0.939, P = 0.033). Conclusion: Postoperative SGLT2i use correlates with lower 12-month AF recurrence risk in first-time CA patients, suggesting SGLT2i as a potential adjuvant therapy. Given the observational nature of this study, these findings should be considered hypothesis-generating. Large-scale multicenter randomized controlled trials are needed for verification.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.